Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY

Daily Recap - TUESDAY https://t.co/Vq5BSHmPsv

• Dr. John Cush

Congrats to Dr Kaitlin McCarter for her #ACR23 investigating predictors and mortality of pre-existing RA flare after immune checkpoint inhibitor. 46% flared Seropositive- OR 2.0 NO association with mortality -ICIs are safe to use in RA -Flares are not a proxy of efficacy https://t.co/eoy0FJb1nA

LNK01001 12 mg or 24 mg BID to 24 weeks in moderate to severe RA achieved ACR 20 (91.1%, 90.7% respectively), were generally safe, well tolerated with most TEAEs being mild to moderate. Effect seen in Week 1. Wu C, Late breaking Abst#L09 #ACR23 @RheumNow https://t.co/M29LYtEs9I

#ACR23 Abs #L07 data do not support tapering of TNFi treatment among RA patients in sustained remission in 3 year study. https://t.co/d0ZBWDKZlB https://t.co/EdllyGUT1y

Rx of #inflammatory #arthritis with #glucocorticoids doesn’t seem to affect outcomes in #malignancy treated with #checkpoint #inhibitors. Good news as new or flaring inflammatory arthritis as an irAE can be severe. #ACR23 @RheumNow @ACRheum #1055 @CanRIO_Tweets https://t.co/tFIPcQq2X6

Tapering ABA vs. stable dose ABA in RA No diff in DAS28 remission at 2 years But… Only in patients receiving concomitant MTX Those tapering ABA mono also experience higher functional important Of note: not an RCT @RheumNow #ACR23 ABST2542 https://t.co/yycCDTnRiF

The ADIRA trial showed no significant difference in change in DAS28 bet grps in the adjusted analysis. Intervention included food delivery svc & probiotic shot Limitations included study design issues such small sample size #ACR23 @RheumNow @rheumarhyme https://t.co/J6LEb0yONS